Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Accumulated Expenses (2022 - 2025)

Historic Accumulated Expenses for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $15.5 million.

  • Entrada Therapeutics' Accumulated Expenses rose 1588.45% to $15.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.5 million, marking a year-over-year increase of 1588.45%. This contributed to the annual value of $13.3 million for FY2024, which is 1781.9% up from last year.
  • As of Q3 2025, Entrada Therapeutics' Accumulated Expenses stood at $15.5 million, which was up 1588.45% from $11.8 million recorded in Q2 2025.
  • Entrada Therapeutics' 5-year Accumulated Expenses high stood at $15.5 million for Q3 2025, and its period low was $4.5 million during Q1 2022.
  • Moreover, its 4-year median value for Accumulated Expenses was $11.0 million (2024), whereas its average is $10.0 million.
  • As far as peak fluctuations go, Entrada Therapeutics' Accumulated Expenses skyrocketed by 15809.02% in 2023, and later crashed by 2470.02% in 2024.
  • Entrada Therapeutics' Accumulated Expenses (Quarter) stood at $7.6 million in 2022, then soared by 49.49% to $11.3 million in 2023, then increased by 17.82% to $13.3 million in 2024, then increased by 16.41% to $15.5 million in 2025.
  • Its Accumulated Expenses was $15.5 million in Q3 2025, compared to $11.8 million in Q2 2025 and $7.6 million in Q1 2025.